Major medical bodies have issued significant updates to cancer screening guidelines in 2026, affecting breast, cervical, and gastric cancer detection strategies. The changes emphasize personalized, ...

HealthDay News — Combining human papillomavirus (HPV) DNA testing with cytology testing at first screening resulted in fewer cases of high-grade cervical intraepithelial neoplasia (CIN) lesions and ...

Testing for low-risk human papillomavirus (HPV) types should be excluded from cervical cancer screening because such tests fail to predict risk of developing cervical intraepithelial neoplasia (CIN) ...

Abbott Laboratories is adding HPV screening to its "Alinity m" family of diagnostic assays following U.S. Food & Drug Administration approval. Abbott said in a press release that the FDA approved its ...

Doctors say melanoma and HPV-related cancers are showing up in patients without traditional risk factors, making awareness ...

Illustrative picture of human papillomavirus (HPV) vaccine. Credit: Getty Images. Primary care providers have a critical role in human papillomavirus (HPV) screening and prevention. Human ...

Q: Is there an alternative to the traditional Pap smear for cervical cancer screening? A: Yes, there are now alternatives to ...

This prospective, multicenter validation study accrued patients with stage IB-IVA cervical cancer treated with CRT between 2017 and 2022. Participants underwent phlebotomy at baseline, end of CRT, 4-6 ...

The American College of Obstetricians and Gynecologists has updated its cervical cancer screening guidance to include patient-collected high-risk HPV testing for average-risk adults aged 30–65. This ...

Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical ...

SALT LAKE CITY--(BUSINESS WIRE)--SimplyTest® has launched a groundbreaking saliva-based test to detect high-risk strains of oral human papillomavirus (HPV), a major cause of oropharyngeal cancers.

Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid ...